Krystal Biotech Company Insiders

Krystal Biotech Management Team Effectiveness

The company has return on total asset (ROA) of 0.0891 % which means that it generated a profit of $0.0891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1966 %, meaning that it created $0.1966 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.08 in 2026. Return On Capital Employed is likely to gain to 0.07 in 2026. At this time, Krystal Biotech's Asset Turnover is comparatively stable compared to the past year. Common Stock Shares Outstanding is likely to drop to about 19.6 M in 2026. Net Loss is likely to gain to about (119.7 M) in 2026The majority of Krystal Biotech outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Krystal Biotech to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Krystal Biotech. Please pay attention to any change in the institutional holdings of Krystal Biotech as this could imply that something significant has changed or is about to change at the company. Some institutional investors establish a significant position in stocks such as Krystal Biotech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Krystal Biotech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Krystal Biotech Workforce Comparison

Krystal Biotech Profit Margins

The company has Profit Margin (PM) of 0.53 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42.

Krystal Biotech Insider Trading History

Krystal Biotech Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Krystal Biotech often depends on how effective the management is. Krystal Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Krystal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Krystal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Krystal Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Krystal Biotech. Check Krystal Biotech's Beneish M Score to see the likelihood of Krystal Biotech's management manipulating its earnings.

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.